Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Twist Bioscience Corp TWST

Healthcare Biotechnology
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of... see more

Recent & Breaking News (NDAQ:TWST)

Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls

Business Wire June 11, 2020

Twist Bioscience Partners with Serimmune to Identify SARS-CoV-2 Therapeutic Antibody Candidates

PR Newswire June 9, 2020

Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire June 8, 2020

Twist Bioscience Announces Pricing of a $100 Million Public Offering of Common Stock

Business Wire June 3, 2020

Twist Bioscience Announces Proposed Public Offering of Common Stock

Business Wire June 3, 2020

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection

Business Wire June 1, 2020

Twist Bioscience to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 26, 2020

Twist Bioscience to Participate in the UBS Virtual Global Healthcare Conference

Business Wire May 12, 2020

Twist Bioscience Reports Second Quarter Fiscal 2020 Financial Results

Business Wire May 7, 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Business Wire May 6, 2020

Twist Bioscience to Report Fiscal 2020 Second Quarter Financial Results on Thursday, May 7, 2020

Business Wire April 30, 2020

Twist Bioscience Expands Flexibility of Clonal Genes for Pharmaceutical, Biotechnology and Industrial Chemical Research

Business Wire April 20, 2020

Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19

Business Wire March 26, 2020

Twist Bioscience Synthetic SARS-CoV-2 RNA Controls Added to FDA Website as Reference Materials

Business Wire March 25, 2020

Twist Announces Availability of Next-Generation Sequencing Target Enrichment Panel for SARS-CoV-2/COVID-19 Research

Business Wire March 16, 2020

Twist Bioscience Announces Availability of Synthetic SARS-CoV-2 RNA Controls

Business Wire March 12, 2020

Twist Bioscience and SOPHiA GENETICS Collaborate to Offer Optimized Genomic Solutions

Business Wire February 26, 2020

Twist Bioscience to Present at the Cowen 40th Annual Health Care Conference

Business Wire February 26, 2020

Twist Bioscience and Miroculus Agree to Collaborate on Next-Generation Sequencing Target Enrichment and Library Preparation Tools for Clinical Research

Business Wire February 25, 2020

Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire February 24, 2020